Enzo Biochem (NYSE:ENZ) Trading Up 8.3%

Enzo Biochem, Inc. (NYSE:ENZ) shares were up 8.3% on Wednesday . The stock traded as high as $4.46 and last traded at $4.31. Approximately 703,556 shares were traded during mid-day trading, an increase of 261% from the average daily volume of 194,659 shares. The stock had previously closed at $3.98.

The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.38 and a current ratio of 3.83.

Enzo Biochem (NYSE:ENZ) last issued its earnings results on Monday, June 10th. The medical research company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. Enzo Biochem had a negative return on equity of 29.83% and a negative net margin of 25.55%. The company had revenue of $19.66 million for the quarter.

In other news, major shareholder Discovery Fund Lp Harbert bought 102,118 shares of the company’s stock in a transaction on Thursday, May 30th. The shares were bought at an average cost of $3.09 per share, with a total value of $315,544.62. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Harbert Management Corp bought 63,677 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was purchased at an average cost of $3.09 per share, for a total transaction of $196,761.93. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 179,927 shares of company stock worth $563,323. Insiders own 9.40% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of Enzo Biochem by 26.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,715,398 shares of the medical research company’s stock worth $11,188,000 after acquiring an additional 565,126 shares in the last quarter. Strs Ohio boosted its stake in shares of Enzo Biochem by 9.9% during the 4th quarter. Strs Ohio now owns 186,100 shares of the medical research company’s stock worth $517,000 after acquiring an additional 16,800 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Enzo Biochem by 46.4% during the 4th quarter. Rhumbline Advisers now owns 60,542 shares of the medical research company’s stock worth $168,000 after acquiring an additional 19,181 shares in the last quarter. Prudential Financial Inc. bought a new stake in shares of Enzo Biochem during the 4th quarter worth about $33,000. Finally, BlackRock Inc. boosted its stake in shares of Enzo Biochem by 0.4% during the 4th quarter. BlackRock Inc. now owns 4,010,279 shares of the medical research company’s stock worth $11,149,000 after acquiring an additional 17,405 shares in the last quarter. 68.03% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.themarketsdaily.com/2019/06/13/enzo-biochem-nyseenz-trading-up-8-3.html.

About Enzo Biochem (NYSE:ENZ)

Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.

Further Reading: The Role of a Fiduciary and Individual Investors

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.